Synthesis of Sulfonamide-Based Schiff Bases as Potent Anticancer Agents: Spectral Analyses, Biological Activity, Molecular Docking, ADME, DFT, and Pharmacophore Modelling Studies

ArticleAçık Erişim

Özet

The current study focuses on the synthesis and characterization of six benzenesulfonamide-based Schiff base derivatives (7–12) with various electron-withdrawing and electron-donating substituents (−F, -CI, -Br, −CH3, and −OCH3) and the assessment of their antiproliferative activities against human lung (A549) and liver (HepG2) cancer cell lines using in vitro and in silico approaches. The structures of the synthesized compounds (7–12) were elucidated by elemental analysis and FT-IR, 1D (1H, 13C, APT, and DEPT-135), and 2D (HMQC and HMBC) NMR spectroscopies. The cytotoxic activities of the targeted compounds were determined at various concentrations against these cancer cell lines for 72 h, using the MTT method. The targeted molecules (7–12) demonstrated remarkable antiproliferative activities, with IC50 values ranging from 6.032–9.533 μM against the A549 cell line and 5.244–9.629 μM against the HepG2 cell line. These compounds showed activities at lower or very similar concentrations to cisplatin against the A549 cell line and at much lower concentrations than cisplatin against the HepG2 cell line. Among them, compounds 10 and 12 were found to be more effective against A549 and HepG2 cells, respectively, than cisplatin. These compounds were analyzed by interacting with the 1BNA, 4HJO, and 4ASD crystal structures in molecular docking studies. The docking score of 4ASD-compound 12 interaction was calculated as −4.045 kcal/mol, 4HJO-compound 10 interaction was calculated as −5.179 kcal/mol and 1BNA-compound 10 interaction was calculated as −8.571 kcal/mol and it was determined that these compounds were theoretically better than Cisplatin. In the present study, ADME data were estimated using the web tool SwissADME. With ADME, it was calculated that the logP value of compounds 7–12 was less than 5, the HBD number was 1, the HBA number was 7 or 8, and the molecular weight was less than 500. Properties such as the electrophilic index and chemical hardness of the designed compounds were examined by density functional theory (DFT) using B3LYP/6-311G**. In conclusion, these compounds have emerged as promising new anti-cancer drug candidates. © 2024 Wiley-VHCA AG, Zurich, Switzerland.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/11505Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1002/cbdv.202402229Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorBaşaran, Eyüp
dc.contributor.authorÇakmak, Reşit
dc.contributor.authorTürkmenoğlu, Burçin
dc.contributor.authorAkkoc, Senem
dc.contributor.authorKöprü, Semiha
dc.date.accessioned2026-10-18T20:26:32.846959251Z
dc.date.available2026-10-18T20:26:32.846959251Z
dc.date.issued2025
dc.description.abstractThe current study focuses on the synthesis and characterization of six benzenesulfonamide-based Schiff base derivatives (7–12) with various electron-withdrawing and electron-donating substituents (−F, -CI, -Br, −CH3, and −OCH3) and the assessment of their antiproliferative activities against human lung (A549) and liver (HepG2) cancer cell lines using in vitro and in silico approaches. The structures of the synthesized compounds (7–12) were elucidated by elemental analysis and FT-IR, 1D (1H, 13C, APT, and DEPT-135), and 2D (HMQC and HMBC) NMR spectroscopies. The cytotoxic activities of the targeted compounds were determined at various concentrations against these cancer cell lines for 72 h, using the MTT method. The targeted molecules (7–12) demonstrated remarkable antiproliferative activities, with IC50 values ranging from 6.032–9.533 μM against the A549 cell line and 5.244–9.629 μM against the HepG2 cell line. These compounds showed activities at lower or very similar concentrations to cisplatin against the A549 cell line and at much lower concentrations than cisplatin against the HepG2 cell line. Among them, compounds 10 and 12 were found to be more effective against A549 and HepG2 cells, respectively, than cisplatin. These compounds were analyzed by interacting with the 1BNA, 4HJO, and 4ASD crystal structures in molecular docking studies. The docking score of 4ASD-compound 12 interaction was calculated as −4.045 kcal/mol, 4HJO-compound 10 interaction was calculated as −5.179 kcal/mol and 1BNA-compound 10 interaction was calculated as −8.571 kcal/mol and it was determined that these compounds were theoretically better than Cisplatin. In the present study, ADME data were estimated using the web tool SwissADME. With ADME, it was calculated that the logP value of compounds 7–12 was less than 5, the HBD number was 1, the HBA number was 7 or 8, and the molecular weight was less than 500. Properties such as the electrophilic index and chemical hardness of the designed compounds were examined by density functional theory (DFT) using B3LYP/6-311G**. In conclusion, these compounds have emerged as promising new anti-cancer drug candidates. © 2024 Wiley-VHCA AG, Zurich, Switzerland.
dc.description.sponsorshipFunding text 1: EB and RC would like to thank Batman University for providing laboratory support. SA would like to thank the S\u00FCleyman Demirel University Research Fund (project number TSG-2024-9516) for financial support for cell culture studies. The authors would like to thank Erzincan Binali Y\u0131ld\u0131r\u0131m University, especially the Basic Sciences Application and Research Center (EBYU-EUTAM), for providing the Schr\u00F6dinger Maestro 2021\u20132 program.; Funding text 2: EB and RC would like to thank Batman University for providing laboratory support. SA would like to thank the S\u00FCleyman Demirel University Research Fund (project number TSG\u20102024\u20109516) for financial support for cell culture studies. The authors would like to thank Erzincan Binali Y\u0131ld\u0131r\u0131m University, especially the Basic Sciences Application and Research Center (EBYU\u2010EUTAM), for providing the Schr\u00F6dinger Maestro 2021\u20132 program.
dc.identifier.doi10.1002/cbdv.202402229
dc.identifier.eissn1612-1880
dc.identifier.issn1612-1872
dc.identifier.issue2
dc.identifier.pmid39439182
dc.identifier.scopus2-s2.0-85208595113
dc.identifier.startpagee202402229
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/11505
dc.identifier.volume22
dc.identifier.wosWOS:001354649600001
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofChemistry and Biodiversity
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectChemotherapeutic drug candidate
dc.subjectin silico study
dc.subjectSchiff base derivative
dc.subjectSulfonamide
dc.subjectAntineoplastic Agents
dc.subjectCell Line, Tumor
dc.subjectCell Proliferation
dc.subjectDensity Functional Theory
dc.subjectDose-Response Relationship, Drug
dc.subjectDrug Screening Assays, Antitumor
dc.subjectHep G2 Cells
dc.subjectHumans
dc.subjectMolecular Docking Simulation
dc.subjectMolecular Structure
dc.subjectPharmacophore
dc.subjectSchiff Bases
dc.subjectStructure-Activity Relationship
dc.subjectSulfonamides
dc.subject1 [[(4 sulfamoylphenethyl)imino]methyl]naphthalen 2 yl 4 bromobenzenesulfonate
dc.subject1 [[(4 sulfamoylphenethyl)imino]methyl]naphthalen 2 yl 4 methoxybenzenesulfonate
dc.subjectantineoplastic agent
dc.subjectcisplatin
dc.subjectSchiff base
dc.subjectunclassified drug
dc.subjectA-549 cell line
dc.subjectantineoplastic activity
dc.subjectantiproliferative activity
dc.subjectArticle
dc.subjectcarbon nuclear magnetic resonance
dc.subjectcomparative effectiveness
dc.titleSynthesis of Sulfonamide-Based Schiff Bases as Potent Anticancer Agents: Spectral Analyses, Biological Activity, Molecular Docking, ADME, DFT, and Pharmacophore Modelling Studies
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus11
rdl.citation.wos12
rdl.departmentErzincan Binali Yıldırım University, Faculty of Pharmacy, Department of Analytical Chemistry, Erzincan, 24002, Türkiye.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)